Tianjin Tianyao Pharmaceuticals (600488) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

CN Stock MarketDetailed Quotes

600488 Tianjin Tianyao Pharmaceuticals

Watchlist

4.07
-0.01-0.25%

Market Closed Jan 15 15:00 CST

4.44BMarket Cap29.28P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Tianjin Tianyao Pharmaceuticals Gets Listing Approval for Dexamethasone Sodium Phosphate API in Brazil
MT NewswiresJan 2 02:55 ET
Tianjin Tianyao Pharmaceuticals Co., Ltd.'s (SHSE:600488) Prospects Need A Boost To Lift Shares
Simply Wall StDec 24, 2024 02:49 ET
Tianjin Tianyao Pharmaceuticals Gets China Nod for Autoimmune Anti-Inflammatory Injection
MT NewswiresNov 29, 2024 02:49 ET
Tianyao Pharmaceuticals Unit Gets China Nod for Additional Specifications for Anti-Wheezing Drug
MT NewswiresNov 11, 2024 02:44 ET
Should You Be Adding Tianjin Tianyao Pharmaceuticals (SHSE:600488) To Your Watchlist Today?
Simply Wall StOct 28, 2024 18:55 ET
Tianjin Tianyao Unit's Lincomycin Hydrochloride Injection Passes Drug Consistency Evaluation
MT NewswiresOct 16, 2024 03:19 ET

Comments

Moomoo AI

Jan 24, 2024 20:03

Tianjin Tianyao Pharmaceuticals' high P/E ratio is alarming due to its three-year growth being lower than market predictions. If recent earnings trends persist, shareholders' investments could be at risk and potential investors may pay an excessive premium.

Earnings Not Telling The Story For Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE:600488)

Moomoo AI

Nov 23, 2023 16:49

Despite a decrease in earnings per share, the company's stock continues to rise, suggesting expected future growth. Over the last five years, a 44% shareholder return, largely due to dividends, denotes positivity.